Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prevention of diabetes by administration of GnRH antagonists

a technology of gnrh and antagonists, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorder, etc., can solve the problems of affecting the normal functioning of the body, affecting the function of the body, and literally starving the cells of the body to death

Inactive Publication Date: 2002-08-01
CHILDRENS MERCY HOSPITAL
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diabetes is one of the most costly health problems in America.
Since glucose cannot enter the cells, it builds up in the blood and the body's cells literally starve to death.
However, most studies of gender differences in autoimmunity are performed in vivo, where manipulations such as gonadectomy or administration of gonadal steroids will necessarily alter feedback effects on hypothalamic and pituitary hormones, some of which are now known to be immunomodulatory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention of diabetes by administration of GnRH antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] In this example, intact and gonadectomized non-obese mousen model of diabetes (NOD mouse) mice were treated with GnRH agonists and antagonists to determine the effect thereof on serum IgG levels and the incidence and onset of diabetes.

METHODS

Mice

[0021] The well-characterized NOD mice were used throughout the study. Male and female mice were purchased from the Jackson Laboratory (Bar Harbor, Me.). These mice are art-recognized animal models used in diabetes research. (Makino et al., (1980) Breeding of a Non-obese Diabetic Strain of Mice. Exp Anim, 29, 1-13; Miyazaki, A. T., et al, (1985) Predominance of T Lymphocytes in Pancreatic Islets and Spleen in Prediabetic Non-obese Diabetic (Nod) Mice: a Longitudinal Study. Clin Exp immunol, 60, 622-630)

Experimental Design

[0022] Both intact and gonadectomized mice (GDX) were used. Gonadectomies were performed to demonstrate an increase in the incidence of diabetes and also order to eliminate the variable of sex hormone production. To c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Login to View More

Abstract

A method for reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals (e.g., mice, rats, humans) is provided wherein the mammals are treated with a gonadotropin-releasing hormone (GnRH) antagonist. Preferably, the antagonist is administered repeatedly over time by subcutaneous injection. A useful antagonist is Acetyl-beta-[2-Naphthyl]-D-Ala-D-p-Chloro-Phe-beta-[3-Pyridyl]-D-Ala-Ser-Nepsi-[Nicotinoyl]-Lys-Nepsi-[Nicotinoyl]-D-Lys-Leu-Nepsi-[Isopropyl]-Lys-Pro-D-Ala-NH2. Other useful antagonists are Nal-Glu, PPI-149 and acryline.

Description

[0001] 1. Field of the Invention[0002] The present invention is directed to a method of reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals by the administration to the mammal of an effective amount of a gonadatropin-releasing hormone (GnRH) antagonist. The administration of such an antagonist gives statistically significant reductions in diabetes incidence and / or onset.[0003] 2. Description of the Prior Art[0004] There are 15.7 million people (5.9% of the population) in the United States who have diabetes. An estimated 10.3 million people have been diagnosed with diabetes, while 5.4 million people are unaware that they have a disease. Each day approximately 2,200 people are diagnosed with diabetes. Diabetes is the seventh leading cause of death (sixth-leading cause of death by disease) in the United States. Diabetes is a chronic disease that has no cure. Diabetes is one of the most costly health problems in America. Health care and other costs d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61K45/00A61K38/04A61K38/09A61P3/10C07K7/06
CPCA61K38/08A61K38/09A61P5/04A61P3/10A61K38/10
Inventor JACOBSON, JILL D.
Owner CHILDRENS MERCY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com